Log In
Copyright © 2010 American Chemical Society
May 3, 2010 Cover
Volume 88, Issue 18
COVER: Vertex' telaprevir is expected to be one of the first new molecules approved to treat hepatitis C.
Volume 88, Issue 18
HEPATITIS C TREATMENT
In the next year, the expected approval of small molecules targeting hepatitis C will usher in a new era in treatment
COVER: Vertex' telaprevir is expected to be one of the first new molecules approved to treat hepatitis C.
Credit: Robin Braverman/C&EN
» Full Article
May 3, 2010 Issue
Volume 88, Issue 18
May 3, 2010 Issue, Vol. 88 | Iss. 18
In the next year, the expected approval of small molecules targeting hepatitis C will usher in a new era in treatment
(pp. 12-17)
Features
Government & Policy
Offshore drilling is being used as a political chip in an effort to secure a climate deal (pp. 30-33)
Science & Technology
Long overshadowed by amyloid-β, tau protein is gaining ground as a therapeutic target in alzheimer's disease (pp. 36-39)
Cover Story: The Waiting Game
Alternative Interferons
Small molecules aren't the only new drugs in development to treat hepatitis C
Web ExclusiveNews of the Week
Earnings Jump In First Quarter
Recovery: Return of consumer demand brings chemical results closer to prerecession level
(p.7)Biotech Alfalfa Ban Questioned
Biotechnology: Supreme Court hears first case involving a genetically modified crop
(p.8)Charles River To Acquire WuXi
Contract Services: $1.6 billion deal creates an integrated drug discovery and clinical development services company
(p.9)New Editor For Organometallics
Publishing: Texas A&M's John Gladysz succeeds journal's founding editor
(p.9)Academy Elects New Members
Honors: Ninety scientists join the ranks of the National Academy of Sciences
(p.10)Renewing America Competes Act
Legislation: House committee clears bill to continue investment in science, innovation, and education
(p.10)Creating Fuel From Water
Sustainable Energy: New materials aim to improve the path to dihydrogen
(p.11)Eastman Aims To Sell Its Polyester Unit
Plastics: A sale would complete the firm's exit from the PET business
(p.11)Departments
Business
Some small custom chemical companies survive the recession and defy the move offshore
(pp. 26-28)
In the next year, the expected approval of small molecules targeting hepatitis C will usher in a new era in treatment
(pp. 12-17)
When in Cambridge, major drug companies play by Cambridge rules in a quest for breakthroughs
(pp. 20-24)
Researchers gaining exposure to industrial science are encouraged to publish
Web Exclusive
Small molecules aren't the only new drugs in development to treat hepatitis C
Web Exclusive
ACS News
Chemists can gear up for the celebration by getting involved in upcoming outreach activities
(pp. 45-46)
Chemists abroad can find an ACS community in their own backyard—or they can form their own
(p.47)
Government & Policy
Offshore drilling is being used as a political chip in an effort to secure a climate deal
(pp. 30-33)
Science & Technology
Long overshadowed by amyloid-β, tau protein is gaining ground as a therapeutic target in alzheimer's disease
(pp. 36-39)
Chemical innovations make tasty battlefield meals, ready-to-eat
(pp. 40-41)
Fluorine Chemistry: New generation of safer compounds will benefit pharmaceuticals and agrochemicals
(p.35)Career & Employment
Large-molecule research is a warm spot for chemists in today’s chilly job market
(pp. 50-52)